XOMA Corp Pref Share 8.625 Perp 12/15/21 | 8-K: FY2025 Q3 Revenue: USD 9.351 M

Revenue: As of FY2025 Q3, the actual value is USD 9.351 M.

EPS: As of FY2025 Q3, the actual value is USD 0.7.

EBIT: As of FY2025 Q3, the actual value is USD 1.971 M.

Segment Revenue

• Income and revenue for the three and nine months ended September 30, 2025, were $9.4 million and $38.4 million, respectively, compared with $7.2 million and $19.8 million for the corresponding periods of 2024. The increase was primarily driven by increased income related to VABYSMO and OJEMDA.

Operational Metrics

• Net Income: XOMA Royalty reported net income of $14.1 million and $25.6 million for the three and nine months ended September 30, 2025, as compared to net losses of $17.2 million and $9.9 million in the corresponding periods of 2024.
• Operating Profit: Income (Loss) from operations was - $1.3 million for the three months ended September 30, 2025, compared to - $15.6 million for the same period in 2024. For the nine months ended September 30, 2025, it was $9.2 million compared to - $32.7 million in 2024.
• Operating Costs: R&D expenses for the three and nine months ended September 30, 2025, were $69 thousand and $1.4 million, respectively, compared with $0.8 million and $2.0 million for the corresponding periods of 2024. G&A expenses for the three and nine months ended September 30, 2025, were $9.7 million and $25.7 million, respectively, compared with $8.0 million and $27.5 million for the corresponding periods of 2024.

Cash Flow

• Operating Cash Flow: Net cash provided by operating activities was $8.4 million for the nine months ended September 30, 2025, compared to - $10.8 million for the same period in 2024.

Unique Metrics

• Cash Receipts: In the first nine months of 2025, XOMA Royalty received $43.9 million in cash from partners, including $30.3 million in royalties and $13.6 million in milestone payments and fees. In the third quarter, they received $14.3 million in cash from commercial sales.
• Gains on Acquisitions: In the third quarter of 2025, XOMA Royalty recorded gains on acquisitions of $17.9 million for HilleVax and $1.8 million for Turnstone.

Outlook / Guidance

• XOMA Royalty anticipates several clinical readouts over the coming months and quarters that, if positive, can meaningfully shape their business trajectory.